Novoxel
Skin Rejuvenation Technology
StartupNovoxel is a Netanya-based startup in the Health Tech & Life Sciences sector, established in 2011. Skin Rejuvenation Technology. Novoxel was founded by Michael Slatkine and Jacob Zlochover. The company has 11-50 employees.
The company follows a B2B business model. Product stage: Released.
- StageMature
- ProductReleased
- ModelB2B
- Employees11-50
- HQNetanya
- DistrictCenter District
- Last RoundUndisclosed
Michael SlatkineCo-founder
Jacob ZlochoverCo-founder
3 articles covered by sources including aestheticmed.co.uk,
www.a2magazine.co.za,
www.dailymail.co.uk.
What does Novoxel do?
Novoxel has developed a fractional, microtip aesthetic technology for thermomechanical ablation (TMA). TMA is a platform for the development of lightweight, miniaturized, and cost-effective products. The companys Tixel technology allows precise, accurate, and painless tissue evaporation without undesired thermal damage to surrounding healthy tissue. Tixel is a non-laser fractional treatment technology that can transfer thermal energy to the skin quickly and safely. Its treatments are safe, with short healing times. Tixel is versatile, covering the treatment spectrum of both superficial and deep ablative lasers, and can also be set to nonablative mode in order to transfer heat to the dermis while sparing the epidermis. Novoxels Mezotix technology transfers pure heat to the skin quickly and safely through very brief contact. The thermal effect induces renewal of epidermal cells and regeneration of collagen in the dermis.
Who founded Novoxel?
Novoxel was founded in 2011 by Michael Slatkine (Co-founder), Jacob Zlochover (Co-founder ).
What sector is Novoxel in?
Novoxel operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Novoxel located?
Novoxel is based in Ha-Melakha Street 43, Netanya, Israel, Center District. The company also has offices abroad.